Bringspring Science and Technology Co., Ltd. primarily engages in the smart healthcare business in China. It operates through Health Care and Social Security, Government and Public Utilities, and Others segments. The company’s smart medical records services include medical record statistics management, integrated medical records, medical record tracing, digital medical records, paperless medical record management, micro medical records, and self-service printing terminals. Its DRG/DIP services also comprise DRG medical insurance operation supervision systems, DRG medical service operation supervision systems, medical insurance settlement list reporting, and DIP medical insurance operation supervision systems; and medical quality control services include medical record homepage quality control system, medical insurance intelligent review system, medical insurance settlement list management system, and full-process medical record quality control system. In addition, the company’s medical management services comprise hospital grade review, single disease management system, medical safety (adverse) event management system, and digital follow-up system; and data analysis and reporting services include performance appraisal homepage report, HQMS, respiratory diseases, NCIS medical services and quality safety, national drugs and consumables, and anti-tumor drugs, as well as medical platform services comprise provincial and municipal comprehensive supervision platform, public hospital performance assessment, and medical insurance payment platform. Further, it offers smart city solutions and artificial intelligence applications. The company was founded in 2005 and is headquartered in Shenyang, China.
Metrics to compare | 300290 | Sector Sector - Average of metrics from a broad group of related Technology sector companies | Relationship Relationship300290PeersSector | |
---|---|---|---|---|
P/E Ratio | −778.9x | −24.5x | 11.8x | |
PEG Ratio | 4.22 | 0.02 | 0.01 | |
Price/Book | 14.4x | 4.5x | 2.4x | |
Price / LTM Sales | 14.9x | 8.5x | 2.2x | |
Upside (Analyst Target) | - | 12.9% | 19.0% | |
Fair Value Upside | Unlock | −21.3% | 5.6% | Unlock |